(MENAFN – AETOSWire) (BUSINESS WIRE )–Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481 ) and. ..
(MENAFN – AETOSWire) (BUSINESS WIRE )–Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481 ) and. ..